The acquisition – terms of which have not been disclosed – is expected to close at the end of the month.
Burnaby, Canada-based Transferra – previously known as Northern Lipids – has a portfolio of liposomal drug delivery systems. The firm also provides process development, analytical support services and the production of clinical trial materials.
Reiner Beste, chairman of the board of Evonik Nutrition & Care GmbH, said: “This transaction reflects our continued commitment to growth in the health care area and in the drug delivery space in particular.”
This was echoed by Jean-Luc Herbeaux, head of the Health Care Business Line at Evonik.
“The combination of the drug delivery businesses of Transferra and Evonik will form a leading service provider providing a full array of services, ranging from prototype identification to commercial manufacturing.”
Evonik’s last delivery technology focused agreement was in 2011 when it acquired the assets of SurModics in a deal that also saw it buy the latter’s manufacturing facility in Birmingham, Alabama.